Sanofi Expects Competition From Biosimilar Lantus In Europe In The Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
The French multinational also expects generic versions of Plavix in Japan and Lovenox biosimilars in Europe, but it has a flurry of new products to fall back on, including the recently approved Praluent.